A Possible Role of Galectin-9 in the Pulmonary Fibrosis of Patients with Interstitial Pneumonia
详细信息 查看全文
- 作者：Nobuhiro Matsumoto (1)
Shigeki Katoh (2)
Shigehisa Yanagi (1)
Yasuji Arimura (1)
Masatoshi Tokojima (1)
Masaki Ueno (3)
Mitsuomi Hirashima (4)
Masamitsu Nakazato (1) - 关键词：Galectin ; 9 ; Interstitial pneumonia ; Bronchoalveolar lavage fluid ; Interstitial pneumonia associated with collagen vascular disease
- 刊名：Lung
- 出版年：2013
- 出版时间：April 2013
- 年：2013
- 卷：191
- 期：2
- 页码：191-198
- 全文大小：683KB
- 参考文献：1. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH et al (2002) Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 19:275-83 CrossRef
2. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR et al (1998) Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 157:199-03
3. Flaherty KR, Colby TV, Travis WD, Toews GB, Mumford J, Murray S et al (2003) Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med 167:1410-415 CrossRef
4. Agustí C, Xaubet A, Roca J, Agustí AG, Rodriguez-Roisin R (1992) Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a 2?years follow up. Thorax 47:1035-040 CrossRef
5. Wada J, Kanwar YS (1997) Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J Biol Chem 272:6078-086 CrossRef
6. Perillo NL, Marcus ME, Baum LG (1998) Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death. J Mol Med (Berl) 76:402-12 CrossRef
7. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS (1997) Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. J Clin Investig 99:2452-461 CrossRef
8. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S et al (1998) Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 273:16976-6984 CrossRef
9. Asakura H, Kashio Y, Nakamura K, Seki M, Dai S, Shirato Y et al (2002) Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol 169:5912-918
10. Hirashima M, Kashio Y, Nishi N, Yamauchi A, Imaizumi TA, Kageshita T et al (2004) Galectin-9 in physiological and pathological conditions. Glycoconj J 19:593-00 CrossRef
11. Yamamoto H, Kashio Y, Shoji H, Shinonaga R, Yoshimura T, Nishi N et al (2007) Involvement of galectin-9 in guinea pig allergic airway inflammation. Int Arch Allergy Immunol 143(Suppl 1):95-05 CrossRef
12. Katoh S, Nobumoto A, Matsumoto N, Matsumoto K, Ehara N, Niki T et al (2010) Involvement of galectin-9 in lung eosinophilia in patients with eosinophilic pneumonia. Int Arch Allergy Immunol 153:294-02 CrossRef
13. Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai SY, Shinonaga R et al (2007) Galectin-9 inhibits CD44–hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med 176:27-5 CrossRef
14. Arikawa T, Saita N, Oomizu S, Ueno M, Matsukawa A, Katoh S et al (2010) Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation. Eur J Immunol 40:548-58 CrossRef
15. Dai SY, Nakagawa R, Itoh A, Murakami H, Kashio Y, Abe H et al (2005) Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol 175:2974-981
16. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y et al (2005) Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 11:2962-968 CrossRef
17. American Thoracic Society, European Respiratory Society (2002) American Thoracic Society/European Respiratory Society. International Multidisciplinary Consensus. Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277-04
18. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292:344-47 CrossRef
19. Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron PY et al (1996) Assessment of the European classification criteria for Sj?gren’s syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on diagnostic criteria for Sj?gren’s syndrome. Ann Rheum Dis 55:116-21 CrossRef
20. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187-92 CrossRef
21. Katoh S, Matsumoto N, Fukushima K, Mukae H, Kadota JI, Kohno S et al (2000) Elevated chemokine levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. J Allergy Clin Immunol 106:730-36 CrossRef
22. Seki M, Sakata KM, Oomizu S, Arikawa T, Sakata A, Ueno M et al (2007) Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum 56:3968-976 CrossRef
23. Kohno N, Awaya Y, Oyama T, Yamakido M, Akiyama M, Inoue Y et al (1993) KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 148:637-42 CrossRef
24. Shimizu Y, Kabir-Salmani M, Azadbakht M, Sugihara K, Sakai K, Iwashita M (2008) Expression and localization of galectin-9 in the human uterodome. Endocr J 55:879-87 CrossRef
25. Takahashi Y, Fukusato T, Kobayashi Y, Akiyama S, Tamatani T, Shiga J et al (2006) High expression of eosinophil chemoattractant ecalectin/galectin-9 in drug-induced liver injury. Liver Int 26:106-15 CrossRef
26. Imaizumi T, Kumagai M, Sasaki N, Kurotaki H, Mori F, Seki M et al (2002) Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol 72:486-91
27. Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, Zhang S et al (2008) Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J Cancer Res Clin Oncol 134:899-07 CrossRef
28. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ et al (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6:1245-252 CrossRef
29. Nakae S, Iwakura Y, Suto H, Galli SJ (2007) Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 81:1258-268 CrossRef
30. Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N et al (2003) Galectin-9 induces apoptosis through the calcium–calpain–caspase-1 pathway. J Immunol 170:3631-636
31. Cooper DN (2002) Galectinomics: finding themes in complexity. Biochim Biophys Acta 1572:209-31 CrossRef
32. Sato S, Hughes RC (1994) Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of macrophages. J Biol Chem 269:4424-430
33. Kasper M, Hughes RC (1996) Immunocytochemical evidence for a modulation of galectin 3 (Mac-2), a carbohydrate binding protein, in pulmonary fibrosis. J Pathol 179:309-16 CrossRef
34. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K et al (2007) Role of galectin-3 in human pulmonary fibrosis. Allergol Int 56:57-5 CrossRef
35. Li Y, Jiang D, Liang J, Meltzer EB, Gray A, Miura R et al (2011) Severe lung fibrosis requires an invasive fibroblast phenotype regulated by hyaluronan and CD44. J Exp Med 208:1459-471 CrossRef - 作者单位：Nobuhiro Matsumoto (1)
Shigeki Katoh (2)
Shigehisa Yanagi (1)
Yasuji Arimura (1)
Masatoshi Tokojima (1)
Masaki Ueno (3)
Mitsuomi Hirashima (4)
Masamitsu Nakazato (1)
1. Neurology, Respirology, Endocrinology, and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan
2. Department of Respiratory Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan
3. Department of Inflammation Pathology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan
4. Department of Immunology and Immunopathology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan - ISSN：1432-1750
文摘
Background Galectin-9 (Gal-9) is a β-galactoside-binding protein that induces biological reactions, such as cell activation, chemoattraction, and apoptosis. We evaluated the role of Gal-9 in the pathogenesis of interstitial pneumonia (IP). Methods Gal-9 levels in the bronchoalveolar lavage fluid (BALF) of patients with IP associated with collagen vascular disease (CVD-IP) and with idiopathic interstitial pneumonias (IIPs), including idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (idiopathic NSIP), were estimated by enzyme-linked immunosorbent assay. Gal-9 expression in the lungs of these patients was evaluated using immunohistochemistry. The effect of Gal-9 on the growth and apoptosis of human lung fibroblast cells was assessed in vitro. Results Gal-9 levels in the BALF were significantly higher in patients with CVD-IP than in patients with IIPs. Gal-9 levels significantly correlated with both the total cell count and the absolute number of lymphocytes in the BALF of patients with IIPs and CVD-IP. Strong reactivity with anti-Gal-9 antibody was observed in the cytoplasm of alveolar macrophages, lymphocytes, and type II pneumocytes in the lungs of patients with IP. Gal-9 expression in those cells was more remarkable in patients with CVD-IP than in patients with IPF and idiopathic NSIP. Gal-9 suppressed the growth of human lung fibroblast cells in a dose- dependent manner. Gal-9 induced apoptosis of human lung fibroblast cells in a dose-dependent manner. Conclusions Our findings suggest that the expression level of Gal-9 in the lung is increased in patients with CVD-IP and that Gal-9 may have a protective role against pulmonary fibrosis of these patients.